National Health (Pharmaceutical Benefits) (Pharmacist Substitution of Medicines without Prescription during Shortages) Amendment (No. 5) Determination 2022 (Cth)
PB 131 of 2022
National Health (Pharmaceutical Benefits)
(Pharmacist Substitution of Medicines without
Prescription during Shortages) Amendment (No. 5) Determination 2022
I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.
Dated 20 December 2022
Nikolai Tsyganov
Acting Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care
Contents
Name ........................................................................................................................... 1
Commencement .......................................................................................................... 1
Authority ..................................................................................................................... 1
Schedules .................................................................................................................... 1
| Schedule 1—Amendments National Health (Pharmaceutical Benefits) (Pharmacist Substitution of Medicines | 2 |
| without Prescription during Shortages) Determination 2021 | 2 |
1 Name
(1) This instrument is the National Health (Pharmaceutical Benefits) (Pharmacist Substitution of Medicines without Prescription during Shortages) Amendment (No. 5) Determination 2022.
(2) This instrument may also be cited as PB 131 of 2022.
2 Commencement
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
| Commencement information | ||
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | 21 December 2022 | 21 December 2022 |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument.
Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Authority
This instrument is made under subsection 89A(3) of the National Health Act 1953.
4 Schedules
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1 Amendments
Schedule 1—Amendments
National Health (Pharmaceutical Benefits) (Pharmacist Substitution of
Medicines without Prescription during Shortages) Determination 2021
1 Subsection 5(8), after item 23 dealing with isosorbide mononitrate
Insert:
| Prescribed and substitute pharmaceutical benefits | ||
| Item | Column 1 Prescribed pharmaceutical benefit | Column 2 Substitute pharmaceutical benefit |
| 24 | Listed drug: Cefalexin Form: Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL Manner of administration: Oral Brand: any of the following: (a) Cefalexin Sandoz (b) Ibilex 125 (c) Keflex | Listed drug: Cefalexin Form: Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL Manner of administration: Oral Brands: any of the following: (a) Cefalexin Sandoz (b) Ibilex 250 (c) Keflex |
| 25 | Listed drug: Cefalexin Form: Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL Manner of administration: Oral Brand: any of the following: (a) Cefalexin Sandoz (b) Ibilex 125 (c) Keflex | Listed drug: Cefalexin Form: Capsule 250 mg (as monohydrate) Manner of administration: Oral Brands: any of the following: (a) APO-Cephalexin (b) Ibilex 250 (c) Keflex |
| 26 | Listed drug: Cefalexin Form: Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL Manner of administration: Oral Brand: any of the following: (a) Cefalexin Sandoz (b) Ibilex 250 (c) Keflex | Listed drug: Cefalexin Form: Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL Manner of administration: Oral Brands: any of the following: (a) Cefalexin Sandoz (b) Ibilex 125 (c) Keflex |
| 27 | Listed drug: Cefalexin Form: Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL Manner of administration: Oral Brand: any of the following: (a) Cefalexin Sandoz (b) Ibilex 250 (c) Keflex | Listed drug: Cefalexin Form: Capsule 250 mg (as monohydrate) Manner of administration: Oral Brand: any of the following: (a) APO-Cephalexin (b) Ibilex 250 (c) Keflex |
| 28 | Listed drug: Cefalexin Form: Capsule 500 mg (as monohydrate) Manner of administration: Oral Brands: any of the following: (a) APO-Cephalexin (b) Cefalexin Sandoz (c) Cephalex 500 (d) Cephalexin generichealth (e) Ibilex 500 (f) NOUMED CEFALEXIN (g) Keflex | Listed drug: Cefalexin Form: Capsule 250 mg (as monohydrate) Manner of administration: Oral Brand: any of the following: (a) APO-Cephalexin (b) Ibilex 250 (c) Keflex |
0
0
0